NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: CCM International Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

China Paclitaxel Injection Market Keeps A Stable Development Trend Finds CCM International - CCM published a report in July and forecast that China paclitaxel injection market will keep a stable development trend
China Paclitaxel Injection Market Keeps A Stable Development Trend Finds CCM International

 

NewswireToday - /newswire/ - Guangzhou, Guangdong, China, 2010/08/18 - CCM published a report in July and forecast that China paclitaxel injection market will keep a stable development trend.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

paclitaxel APIs (active pharmaceutical ingredients) was called off export rebate from China customs rebate list for new round of economy adjustment and partial reasons of environment protection consideration. Such act will affect export situation for China as one of the most important paclitaxel APIs countries, exporting about 14% of its domestic output according to the data from China Customs. However, the influence of this seems slim on China paclitaxel injection industry, and the market is still stable for a period, according to the survey of CCM International Limited, Chinese market research firm.

A market research report published later July by CCM International, reports that the cancellation of paclitaxel APIs export rebate may increase the supply in domestic market, but the injection market didn’t have sharp reaction so far. Actually, such APIs had some adjustments on export rebate in decade.

With regard to this injection market, policies and pharmaceutical distribution situation are the two key factors.

“By the end of Jun. 2010, many standards about environmental protection, production safety and application safety had been promulgated in China. Chinese government has strengthened pollution and quality control in paclitaxel industry to safeguard public health and eco-balance.” , told by CCM report. Healthcare reform policies issued by China government in 2009, which aim at relieving economic burden of patients, may increase anticancer drug market consumption.

Considering anticancer drug sales market, several substitutes grow rapidly, for instance docetaxel had higher growth rate comparing with pacalitaxel injection about 7% growth rate in 2009. Paclitaxel injection got slower growth rate in these years. The paclitaxel injection production values had reached USD67.21 million for China in 2009, account for 10% of total in world. And the injection domestic market shares were accounted for by domestic products, above 80%, the rest, mainly shared by Bristol-Myers Squibb (Taxol) and Mayne Pharma Pty Ltd (Anzatax). And both of production and sales value figures, will be higher in the next five years forecasted by CCM.

About this market share
Abraxis BioScience had launched his ABRAXANE in June 2009 in China, which will give sign for foreign companies that want to share this market, and totally boost paclitaxel injection industry. However, for these companies, the circulation and distribution platform situation should not be omitted. “Paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms.” Such platforms which less acquaintance in first-trail companies are highlighted parts in CCM report.

China paclitaxel injection industry has witnessed significant development from 2005-2009, it’s estimated to go far in the next five years, seems that more companies will be involved in the near future.

About CCM
CCM International, Ltd. (cnchemicals.com) is a world leader in China Market Data and Primary Intelligence. Since 2001, CCM has been providing Market Intelligence Data, Newsletters, Reports, and Dynamic Databases to Fortune 500 companies on five of seven continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: CCM International Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


China Paclitaxel Injection Market Keeps A Stable Development Trend Finds CCM International

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Viya Ding - CNChemicals.com 
+86 20-37616606 emarket3[.]cnchemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any CCM International Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From CCM International Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)